MedPath

Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer

Phase 2
Conditions
Head and Neck Cancer
Registration Number
NCT00003257
Lead Sponsor
Aventis Pharmaceuticals
Brief Summary

RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have recurrent head and neck cancer.

Detailed Description

OBJECTIVES: I. Estimate the objective response rate of Ad5CMV-p53 in patients with recurrent squamous cell carcinoma of the head and neck. II. Evaluate the duration of response, time to disease progression, and overall survival of these patients after this treatment. III. Evaluate the effectiveness of Ad5CMV-p53 in reducing cancer morbidity (pain assessment, analgesic consumption, and Karnofsky performance status). IV. Assess the quality of life of these patients receiving this treatment.

OUTLINE: This is a multicenter, open label study. All patients receive direct intratumoral injections of Ad5CMV-p53 on days 1, 2, and 3 of each 4-week treatment course. Patients are treated for at least 2 courses barring local disease progression or unacceptable adverse events; patients with responding or stable disease receive a maximum of 12 courses. Patients are evaluated for safety 4 weeks from the completion of the last treatment. Quality of life is assessed before, during, and after treatment. Patients are followed every 2 months for up to 18 months or until death.

PROJECTED ACCRUAL: A maximum of 39 patients will be accrued for this study.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
39
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (10)

Sidney Kimmel Cancer Center

πŸ‡ΊπŸ‡Έ

San Diego, California, United States

University of Colorado Cancer Center

πŸ‡ΊπŸ‡Έ

Denver, Colorado, United States

University of Connecticut School of Medicine

πŸ‡ΊπŸ‡Έ

Farmington, Connecticut, United States

Clinical Sciences Building

πŸ‡ΊπŸ‡Έ

Chicago, Illinois, United States

University of Iowa Hospitals and Clinics

πŸ‡ΊπŸ‡Έ

Iowa City, Iowa, United States

University of Kansas Medical Center

πŸ‡ΊπŸ‡Έ

Kansas City, Kansas, United States

Tulane University School of Medicine

πŸ‡ΊπŸ‡Έ

New Orleans, Louisiana, United States

Marlene & Stewart Greenebaum Cancer Center, University of Maryland

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

Albert Einstein Comprehensive Cancer Center

πŸ‡ΊπŸ‡Έ

Bronx, New York, United States

Simmons Cancer Center - Dallas

πŸ‡ΊπŸ‡Έ

Dallas, Texas, United States

Sidney Kimmel Cancer Center
πŸ‡ΊπŸ‡ΈSan Diego, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.